ARIAD Pharmaceuticals Inc

More

• MARKET PULSE-Aruba, Nautilus, EOG, Ducommun, Ruckus, MercadoLibre Tuesday, 7 May 2013 | 11:48 AM ET

  **ARUBA NETWORKS INC, $17.83, down 19 pct. **RUCKUS WIRELESS INC, $14.88, down 22 pct. **MERU NETWORKS, $4.19, down 11 PCT.

• CORRECTED-MARKET PULSE-Aruba, Nautilus, EOG, Ducommun, Ruckus, MercadoLibre Tuesday, 7 May 2013 | 12:42 AM ET

  **ARUBA NETWORKS INC, $17.83, down 19 pct. **RUCKUS WIRELESS INC, $14.88, down 22 pct. **MERU NETWORKS, $4.19, down 11 PCT.

• Doctors Denounce Cancer Drug Price of $100,000 a Year Thursday, 25 Apr 2013 | 10:03 AM ET

  

  A group of doctors likens the high prices for a life-saving medicine as profiteering, akin to jacking up prices of essential goods after a natural disaster. The NYT reports.

• 3 Under-the-Radar Tech Stocks: Top Portfolio Manager Monday, 1 Apr 2013 | 1:37 PM ET

  

  Three tech laggards could have strong upside, Zack Safran of Ivy Science & Technology Fund says.

• UPDATE 2-Biogen wins EU backing for big new MS drug hope Friday, 22 Mar 2013 | 9:50 AM ET

  *Sanofi's rival MS pill Aubagio also recommended by EMA. LONDON, March 22- European regulators have recommended approval of two new multiple sclerosis pills from Biogen Idec and Sanofi, both of which are expected to become major sellers.

• 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

  

  TheStreet.com offers up 13 biotech predictions for 2013.

• How to Profit From Alexza Pharma FDA Ruling Wednesday, 19 Dec 2012 | 12:29 PM ET

  

  Here's how to profit from the coming Alexza FDA run down.

• Number of new drugs picks up in Europe and U.S. Tuesday, 18 Dec 2012 | 12:20 AM ET

  LONDON, Dec 18- The number of new medicines approved or pending approval is on the rise on both sides of the Atlantic, painting an encouraging picture for the global drugs industry as it emerges from a wave of patent expiries.

• UPDATE 2-Ariad gets early FDA approval for leukemia drug Friday, 14 Dec 2012 | 3:53 PM ET

  Dec 14- The U.S. Food and Drug Administration on Friday granted earlier-than-expected approval to Ariad Pharmaceuticals Inc's drug for two rares types of leukemia, but is requiring that patients be warned of potential side effects, sending the company's shares down nearly 20 percent.

• Early Movers: IR, IN, AAPL & More Monday, 10 Dec 2012 | 8:02 AM ET

  

  Some of the names on the move ahead of the open.

• Ariad drug proves effective in curbing chronic leukemia in study Sunday, 9 Dec 2012 | 8:05 AM ET

  Dec 9- An experimental leukemia drug from Ariad Pharmaceuticals Inc eliminated the cancer from the bone marrow of nearly half of patients with a chronic form of the disease who had stopped responding to other drugs, according to a 12- month follow-up of a pivotal drug trial.